lysylglutamic-acid and Diabetes-Mellitus--Type-1

Improving the status of elderly patients with diabetes mellitus is an important issue of gerontology and geriatrics. This work was aimed at the study of the effect of thymomimetic Vilon on the immune status and coagulation hemostasis in elderly patients with type I diabetes mellitus. It was found that the administration of Vilon as an addition to the complex therapy for this cohort of patients resulted in optimization of coagulation hemostasis, which was manifested in the increased content of natural anticoagulants: antithrombin III and protein C, as well as in the stimulation of fibrinolysis. In most cases Vilon reduced the dose of insulin necessary for the stabilization of carbohydrate metabolism. The content of T-helpers, T-dependent and non-T-dependent NK cells was reduced, and the level of active T-lymphocytes, B-lymphocytes and IgA was normalized, which points out the stabilizing effect of Vilon on the immune system and hemostasis.

Topics: Adolescent; Adult; Aged; Aging; Blood Coagulation; Blood Glucose; Diabetes Mellitus, Type 1; Dipeptides; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Immunity, Innate; Insulin; Male; Middle Aged; Severity of Illness Index; Treatment Outcome

It was revealed that patients suffering from the diabetes mellitus type 1 (DM-1) on the stage of destabilization report accelerated blood coagulability, decreased content of natural anticoagulators (antithrombin III and protein C), increased concentration of fibrogene and soluble fibrinmonomer complexes and reduced fibrinolysis. The obtained data testify the development of chronic form of DIC syndrome, moreover there is a correlation between the age of the patient, the severity of the disease, insulin dose, presence and severity of the complications on the one hand and the intensity of DIC syndrome on the other hand. Generally accepted treatment of the DM-1 patients doesn't exert considerable effect on the processes of intravascular blood coagulation. Meanwhile administration of thymomimetic Vilon (Lys-Glu) in these patients significantly reduces or even totally diminishes DIC syndrome. In elderly patients with severe form of the disease the effect of Vilon on coagulative hemostasis and blood fibrinolytic activity is less pronounced.

Topics: Adolescent; Adult; Aged; Aging; Anticoagulants; Blood Coagulation; Blood Glucose; Diabetes Mellitus, Type 1; Dipeptides; Dose-Response Relationship, Drug; Female; Fibrinolysis; Hemoglobins; Humans; Insulin; Male; Middle Aged